TIMI Study Group

Name

TIMI Study Group

Legal name

TIMI Study Group

Website

https://timi.org

Company type

Private

Founded year

1984

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Academic Clinical Research Organization Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (541690)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Clinical Trial Monitoring Support (On-site/Remote) (HLAGACAG)

akta.pro secondary industries

Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Imaging & Cardiac Safety Core Labs (ECOG/EEG/ECG) (HLAGAAAJ)

Keywords

• Academic research organization
• Cardiovascular clinical trials
• Clinical trial management
• Biostatistics services
• Clinical events adjudication

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Trial Sponsorship Contracts: TIMI Study Group generates revenue through contracts with pharmaceutical and biotechnology companies to design, execute, and manage clinical trials. Sponsors include companies developing cardiovascular therapies, lipid-modifying agents, antiplatelet therapies, and other cardiovascular drugs. TIMI provides comprehensive trial services including academic leadership, global trial management, biostatistics, clinical event adjudication, safety monitoring, and core laboratory services.
2. NIH and Government Research Grants: The organization also conducts trials with support from the National Institutes of Health (NHLBI), in addition to industry sponsorship.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

TIMI Study Group is an academic research organization that designs, executes, and manages multicenter cardiovascular clinical trials on behalf of pharmaceutical, biotechnology, and government sponsors. Service lines include academic trial leadership and protocol design, global trial management across a network of more than 5,000 investigators in 50+ countries, biostatistics and clinical prediction modeling, Clinical Events Committee adjudication, Safety Desk reporting, a 24/7 Medical Hotline, and three Core Laboratories for biomarkers, pharmacogenetics, and ECG analysis.

Product overview

TIMI Study Group is an Academic Research Organization (ARO) affiliated with Brigham and Women's Hospital and Harvard Medical School that provides a comprehensive suite of clinical trial services. The core offerings include Academic Trial Leadership for protocol design and guidance, Global Trial Management for site coordination across 50+ countries, TIMI Biostatistics for study design and advanced statistical analysis, Clinical Events Committee for endpoint adjudication, Safety Desk for regulatory-compliant event processing, Medical Hotline for 24/7 physician support, and Core Laboratories for ECG, biomarker, and pharmacogenetic analysis. Supporting tools include TIMI Calculators (interactive risk score calculators) and TIMI Talks Podcast (expert discussions on trial design and cardiology). The organization has conducted over 80 clinical trials enrolling approximately 400,000 patients since 1984.

Differentiator

Problem solved

Functional benefit

Brands

• Critical Care Cardiology Trials Network (CCCTN): A collaborative research network drawn from national leaders in critical care cardiology and coordinated by the TIMI Study Group, dedicated to advancing care of patients requiring cardiac critical care.
• TIMI Biostatistics
• TIMI Biostatistics Core
• Clinical Events Committee (CEC)
• Safety Desk
• Medical Hotline
• Core Labs
• TIMI Biomarker Program
• TIMI Genetics Program
• TIMI ECG Core Laboratory
• TIMI Talks Podcast

Products and services

• Academic Trial Leadership
• Global Trial Management
• TIMI Biostatistics
• Clinical Events Committee (CEC)
• Safety Desk
• Medical Hotline
• Core Labs (Biomarkers, Pharmacogenetics, ECG)
• TIMI Calculators

Quantifiable outcome

• Over 80 clinical trials conducted since 1984 that have shaped cardiovascular care practice
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

One partnership is on record.

• Critical Care Cardiology Trials Network (CCCTN)coreStrategic or Co-development PartnerThe Critical Care Cardiology Trials Network (CCCTN) is a collaborative research network drawn from national leaders in critical care cardiology and coordinated by the TIMI Study Group. The network's mission is to design and execute observational studies and clinical trials that advance the care of patients requiring cardiac critical care. The CCCTN has produced extensive publications in critical care cardiology and operates a multinational registry.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• IQVIA: Largest global CRO offering full-service clinical development including biostatistics, project management, and cardiovascular trials. Competitor to TIMI for mid-tier and large pharma CV trials, but with broader therapeutic and service scope.
• Parexel International: Large global CRO with cardiovascular and biostatistics capabilities competing for pharma-sponsored trials. Broader portfolio than TIMI but overlaps on CV trial design, biostatistics, and global study management.
• ICON plc: Global CRO providing full-service clinical development including biostatistics and cardiovascular outcomes research. Comparable to TIMI on trial execution but with broader therapeutic breadth and commercial scale.
• Medpace Holdings: Mid-to-large CRO with strong cardiovascular franchise and full-service clinical development model. Competes with TIMI for biotech-sponsored CV trials, particularly in metabolic and CV outcomes research.
• Labcorp Drug Development (formerly Covance): Major global CRO with central laboratories, biostatistics, and full-service clinical trial operations. Competes with TIMI for CV trials requiring integrated core lab and project management services at scale.

Direct peers

• Duke Clinical Research Institute (DCRI): Academic research organization within Duke University School of Medicine conducting large-scale cardiovascular and other trials with biostatistics, project leadership, and core lab services. Closest scale competitor to TIMI and benchmark ARO model.
• Population Health Research Institute (PHRI): McMaster University-affiliated ARO conducting large international cardiovascular and metabolic trials with similar global site network and academic leadership structure. Direct peer in terms of trial scope, geographic reach, and CV focus.
• Canadian VIGOUR Centre: University of Alberta-affiliated cardiovascular clinical trials research organization with academic leadership model and international CV trial programs. Comparable ARO peer with similar trial leadership and investigator network orientation.
• Baim Institute for Clinical Research: Academic research organization focused on cardiovascular clinical trials with similar ARO service model (trial design, project management, biostatistics, CEC). Most directly comparable peer to TIMI in scope, structure, and CV therapeutic focus.
• Thrombosis Research Institute: London-based research institute specializing in thrombosis and cardiovascular trials with global investigator network. Comparable to TIMI's antithrombotic trial portfolio and academic research mission.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat7 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/timistudygroup
• LinkedInlinkedin.com/company/timi-study-group

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TIMI Study Group